Graves’ Disease PBMC

Graves’ Disease PBMC for Autoimmune Thyroid Disease Research

Graves’ Disease Human PBMC products are sourced from IRB-consented donors clinically diagnosed with Graves’ disease and processed within 24 hours of collection under standardized SOPs. These cryopreserved peripheral blood mononuclear cells are stored in CryoStor® CS10 and shipped on dry ice. Research Use Only (RUO).

Disease Immunology and Why PBMC

• Graves’ disease is an autoimmune disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TSHR) act as receptor agonists, driving unregulated thyroid hormone production and hyperthyroidism.
• This agonist mechanism distinguishes Graves’ disease from most autoantibody-mediated conditions, where autoantibodies are blocking or destructive rather than stimulating. TSHR antibody status is the defining serological feature.
• Autoantibody production depends on B cells, but requires CD4 T cell help; altered T helper and regulatory T cell balance in circulating lymphocytes is a long-standing focus of research in the disease.
• Thyroid eye disease, or Graves’ orbitopathy, involves orbital fibroblasts that express both TSHR and the insulin-like growth factor 1 receptor; IGF-1R is a validated therapeutic target in that manifestation.
• PBMCs give access to the autoreactive B cell and helper T cell compartments for immunophenotyping, ex vivo antigen stimulation, and repertoire sequencing. Serum and plasma can measure the antibody but cannot interrogate the cells that make it.
• Donor-matched PBMCs also support functional assays for B cell-directed and immunomodulatory therapeutic candidates.

Donor Stratification Available

• TSHR antibody status and titer where documented
• Thyroid function state at collection: untreated hyperthyroid, biochemically euthyroid on therapy, or hypothyroid post-treatment
• Presence and activity of thyroid eye disease
• Treatment status: antithyroid drug therapy, radioiodine, thyroidectomy, biologic therapy, or treatment-naive
• Disease duration and relapse history
• Coexisting autoimmune conditions, plus age, sex, and self-reported race/ethnicity
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed Graves’ disease donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified Graves’ disease diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Thyroid function status, antibody status, and treatment history where available
• Additional Graves’ disease-specific data available upon request

Applications

• Immunophenotyping of B cell, T helper, and regulatory T cell compartments
• Autoreactive B cell characterization and antibody repertoire sequencing
• Ex vivo antigen and mitogen stimulation with cytokine release readouts
• Mechanism-of-action studies for B cell-depleting and immunomodulatory candidates
• IGF-1R and TSHR pathway research relevant to thyroid eye disease
• Bulk and single-cell transcriptomic profiling
• Biomarker discovery and validation for relapse risk
• Drug screening and therapeutic development

Other Graves’ Disease Specimen Types

• Graves’ Disease Plasma
• Graves’ Disease Serum
• Graves’ Disease Whole Blood
• Graves’ Disease Leukopak
• Graves’ Disease Bulk Plasma

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Graves’ Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse all donor cohorts and current stock, visit our human PBMCs page.